BioCentury | Nov 30, 2017
Clinical News
eXIthera reports Phase I data for thrombosis candidate
...company expects to begin Phase II trials of EP-7041, a factor XIa inhibitor, in 2H18. eXIthera Pharmaceuticals Inc....
...pharmacokinetics and clotting biomarker measurements Status: Phase I data Milestone: Start Phase II (2H18) Elizabeth S. Eaton eXIthera Pharmaceuticals Inc. Factor...
...pharmacokinetics and clotting biomarker measurements Status: Phase I data Milestone: Start Phase II (2H18) Elizabeth S. Eaton eXIthera Pharmaceuticals Inc. Factor...
